If you have been reading about nitric oxide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-04. Numbers and descriptions here follow the published literature rather than marketing material.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
=== A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors === A10BH01 Sitagliptin A10BH02 Vildagliptin A10BH03 Saxagliptin A10BH04 Alogliptin A10BH05 Linagliptin A10BH06 Gemigliptin A10BH07 Evogliptin A10BH08 Teneligliptin A10BH51 Sitagliptin and simvastatin A10BH52 Gemigliptin and rosuvastatin
In February 2010, United States Secretary of Defense Robert Gates told his French colleague that "because of Sarkozy's involvement in brokering a ceasefire in Georgia, which Russia was not fully honoring, the sale [of French warships] would send the wrong message to Russia and to our Allies in Central and East Europe." In February 2010, the cable from Baku reported that President of Azerbaijan Ilham Aliyev said that he "has personally witnessed Medvedev taking decisions that then required further approval before they were implemented." The embassy in Moscow dedicated several reports in 2009-2010 to Russia-Israel deal to halt providing Russian S-300 missile system to Iran in exchange for Israel's arms embargo against Georgia.
=== Sewage treatment === Hydrogen peroxide is used in certain waste-water treatment processes to remove organic impurities. In advanced oxidation processing, the Fenton reaction gives the highly reactive hydroxyl radical (•OH). This degrades organic compounds, including those that are ordinarily robust, such as aromatic or halogenated compounds. It can also oxidize sulfur-based compounds present in the waste; which is beneficial as it generally reduces their odour.
direct zoonotic transmission to humans (spillover), assessed as "possible to likely" introduction through an intermediate host followed by a spillover, assessed as "likely to very likely" introduction through the (cold) food chain, assessed as "possible" introduction through a laboratory incident, assessed as "extremely unlikely" The report mentions that direct zoonotic transmission to humans has a precedent, as most current human coronaviruses originated in animals. Zoonotic transmission is also supported by the fact that RaTG13 binds to hACE2, although the fit is not optimal. The investigative team noted the requirement for further studies, noting that these would "potentially increase knowledge and understanding globally."
Yeast taxonomy includes classification of yeast species depending on the presence or absence of a sexual phase. Therefore, some winemaking yeasts are classified by their asexual anamorph (or "imperfect" form) while others may be classified by their sexual teleomorph (or "perfect" form). A common example of this is Brettanomyces (or "Brett") that is usually referenced in wine and viticulture text under its asexual classification though some scientific and winemaking texts may describe specific species (such as Dekkera bruxellensis) under its sporulating sexual classification of Dekkera. Unless otherwise noted, this article will commonly refer to the asexual form of wine yeast. The most common yeast generally associated with winemaking is Saccharomyces cerevisiae which is also used in bread making and brewing. Other genera of yeast that can be involved in winemaking (either beneficially or as the cause of potential wine faults) include:
Sources: en.wikipedia.org
== External South African operations (1978–1984) == Access to Angola provided PLAN with limitless opportunities to train its forces in secure sanctuaries and infiltrate insurgents and supplies across South West Africa's northern border. The guerrillas gained a great deal of leeway to manage their logistical operations through Angola's Moçâmedes District, using the ports, roads, and railways from the sea to supply their forward operating bases. Soviet vessels offloaded arms at the port of Moçâmedes, which were then transshipped by rail to Lubango and from there through a chain of PLAN supply routes snaking their way south towards the border. "Our geographic isolation was over," Nujoma commented in his memoirs. "It was as if a locked door had suddenly swung open...we could at last make direct attacks across our northern frontier and send in our forces and weapons on a large scale." In the territories of Ovamboland, Kaokoland, Kavangoland and East Caprivi after 1976, the SADF installed fixed defences against infiltration, employing two parallel electrified fences and motion sensors. The system was backed by roving patrols drawn from Eland armoured car squadrons, motorised infantry, canine units, horsemen and scrambler motorcycles for mobility and speed over rough terrain; local San trackers, Ovambo paramilitaries, and South African special forces. PLAN attempted hit-and-run raids across the border but, in what was characterised as the "corporal's war", SADF sections largely intercepted them in the Cutline before they could get any further into South West Africa itself.
All the Rh(III) halides are known. Synthesis of many rhodium complexes begin with RhCl3·3H2O, the hydrated trichloride, but RhCl3, the anhydrous form, is largely inert. Other rhodium(III) chlorides include sodium hexachlororhodate, Na3RhCl6, and pentaamminechlororhodium dichloride, [Rh(NH3)5Cl]Cl2. They are used in the recycling and purification of this very expensive metal. Heating a methanolic solution of hydrated rhodium trichloride with sodium acetate gives the blue-green rhodium(II) acetate, Rh2(O2CCH3)4, which features a Rh–Rh bond. This complex and related rhodium(II) trifluoroacetate have attracted attention as catalysts for cyclopropanation reactions. Heating treated with triphenylphosphine in ethanol, hydrated rhodium trichloride converts to RhCl(P(C6H5)3)3. This square planar complex, which is known as Wilkinson's catalyst, is a common and early example of a well-defined homogeneous catalyst for hydrogenation of alkenes.
Type Ia: thin; lax when the elbow is extended and becomes taut when the elbow is flexed. Type Ib: thick; taut even when the elbow is not fully flexed (90°–120°). Under both definitions, Osborne's ligament forms the roof of the cubital tunnel, an opening between the muscles through which the ulnar nerve passes.
=== Use of Oriented Peptide Libraries to determine phosphopeptide binding specificity and protein kinase substrate specificity === In 1994, the Cantley lab published a novel strategy to determine the sequence specificity of phosphopeptide binding domains (initially SH2 domains). Subsequently, the oriented peptide library approach was extended to identify the substrate specificity of protein kinases toward synthetic peptides. This approach was then extended to characterize the specificity of Ser/Thr kinases and phospho-Ser/Thr binding domains. This approach was used to characterize the substrate specificity of a large number of protein kinases. The kinase specificity matrices generated from these experiments served as the basis for creating the website Scansite, allowing the de novo identification of candidate phosphorylation sites in an arbitrary protein. In later research, the oriented peptide library approach has also been used to characterize protease cleavage specificity. Modification of the original oriented peptide approach has allowed for large scale, kinome-wide determination of protein kinase specificity.
==== Peripheral cancers ==== system Xc- function also plays a role in non-neural cancers. Within the gastrointestinal tract, SLC7A11 is upregulated in esophageal, liver, gastric, colorectal, and pancreatic cancers, and inhibition of SLC7A11 has been shown to inhibit tumor progression, likely through induction of ferroptosis. Outside of the gastrointestinal tract, SLC7A11 expression is increased in prostate cancer, bladder cancer, non-small cell lung carcinoma, and melanoma. Inhibition of SLC7A11 in many of these cancers also shows promise in reducing tumor progression.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.